XML 25 R12.htm IDEA: XBRL DOCUMENT

Restructuring Accruals

9 Months Ended

Sep. 30, 2025

Restructuring Accruals

Restructuring Accruals

6. Restructuring Accruals

Selected information related to the restructuring accruals for the three months ended September 30, 2025 and 2024 is as follows:


			Fit to Win program									Other Restructuring
		Employee			Asset			Other			Employee			Asset			Other			Total
		Costs			Impairment			Exit Costs			Costs			Impairment			Exit Costs			Restructuring
Balance at July 1, 2025		$	47		$			$	31		$	5		$			$	3		$	86
Charges			13			36			11												60
Write-down of assets to net realizable value						(36)															(36)
Net cash paid, principally severance and related benefits			(25)						(5)			(1)									(31)
Other, including foreign exchange translation									(2)												(2)
Balance at September 30, 2025		$	35		$	—		$	35		$	4		$	—		$	3		$	77


			Fit to Win program									Other Restructuring
		Employee			Asset			Other			Employee			Asset			Other			Total
		Costs			Impairment			Exit Costs			Costs			Impairment			Exit Costs			Restructuring
Balance at July 1, 2024		$	—		$	—		$	—		$	15		$	—		$	9		$	24
Charges			33			43			4			1						2			83
Write-down of assets to net realizable value						(43)															(43)
Net cash paid, principally severance and related benefits			(1)									(4)						(4)			(9)
Other, including foreign exchange translation			(3)									(1)						(3)			(7)
Balance at September 30, 2024		$	29		$	—		$	4		$	11		$	—		$	4		$	48

Selected information related to the restructuring accruals for the nine months ended September 30, 2025 and 2024 is as follows:


			Fit to Win program									Other Restructuring
		Employee			Asset			Other			Employee			Asset			Other			Total
		Costs			Impairment			Exit Costs			Costs			Impairment			Exit Costs			Restructuring
Balance at January 1, 2025		$	51		$			$	18		$	7		$			$	4		$	80
Charges			71			154			30												255
Write-down of assets to net realizable value						(154)															(154)
Net cash paid, principally severance and related benefits			(94)						(11)			(3)						(1)			(109)
Other, including foreign exchange translation			7						(2)												5
Balance at September 30, 2025		$	35		$	—		$	35		$	4		$	—		$	3		$	77


			Fit to Win program									Other Restructuring
		Employee			Asset			Other			Employee			Asset			Other			Total
		Costs			Impairment			Exit Costs			Costs			Impairment			Exit Costs			Restructuring
Balance at January 1, 2024		$	—		$	—		$	—		$	27		$	—		$	12		$	39
Charges			33			43			4			1						2			83
Write-down of assets to net realizable value						(43)															(43)
Net cash paid, principally severance and related benefits			(1)									(16)						(7)			(24)
Other, including foreign exchange translation			(3)									(1)						(3)			(7)
Balance at September 30, 2024		$	29		$	—		$	4		$	11		$	—		$	4		$	48

When a decision is made to take restructuring actions, the Company manages and accounts for them programmatically apart from the ongoing operations of the business. Information related to major programs is presented separately, while minor initiatives are presented on a combined basis.

As of September 30, 2025, the Company’s only major restructuring program was the Fit to Win initiative, which is expected to reduce redundant production capacity and begin to optimize the network, as well as streamline other cost areas, such as selling, general and administrative expenses. The Fit to Win initiative began in the second half of 2024 and is expected to last at least through 2026. Details regarding charges, payments and other changes to the Fit to Win restructuring accruals are presented in the tables above.

For the three and nine months ended September 30, 2025, the Company recorded restructuring, asset impairment and related charges of approximately $60 million and $255 million (which included $104 million related to its decision to halt the MAGMA program), respectively, to Other expense, net in the Condensed Consolidated Results of Operations, of which all related to the Fit to Win program. For the three months ended September 30, 2025, these charges consisted of employee costs, such as severance and benefit-related costs, write-down of assets and other exit costs in the Americas segment ($59 million) and Europe segment ($1 million). For the nine months ended September 30, 2025, these charges consisted of employee costs, such as severance and benefit-related costs, write-down of assets and other exit costs in the Americas segment ($115 million), Europe segment ($56 million) and Retained corporate costs and other ($84 million). As of September 30, 2025, the Company has incurred cumulative charges of approximately $456 million related to the Fit to Win program.

In October 2025, the Company substantially completed its discussions with certain European Works Councils related to additional indefinite or permanent capacity closures and the elimination of selling, general and administrative positions in Europe (see Note 16 for additional information). Additional restructuring charges are expected in future quarters when management completes their assessment to reduce redundant production capacity and streamline costs. Management does not yet have an estimate for the total restructuring charges to be incurred with this program, however, the total charges are expected to be material. The Company expects that the majority of the remaining cash expenditures related to the accrued employee and other exit costs will be paid out over the next several years.

For the three and nine months ended September 30, 2024, the Company recorded restructuring and related charges of approximately $83 million to Other expense, net ($81 million) and Equity earnings ($2 million) on the Condensed Consolidated Results of Operations, of which $80 million related to the Fit to Win program. These charges consisted of employee costs, such as severance and benefit-related costs, write-down of assets and other exit costs in the Americas segment ($72 million) and Retained corporate costs and other ($11 million).

The Company’s decisions to curtail selected production capacity have resulted in write-downs of certain long-lived assets to the extent their carrying value exceeded fair value or fair value less cost to sell. The Company classified the assumptions used to determine the fair value of the impaired assets in the period that the measurement was taken as Level 3 (third-party appraisals, where applicable) in the fair value hierarchy as set forth in the general accounting principles for fair value measurements. For the asset impairments recorded during the three and nine months ended September 30, 2025, the remaining carrying value of the impaired assets was approximately $0.